Cohance Lifesciences Stock Screener | Share Price & Fundamental Analysis
COHANCE
Pharmaceuticals
Share Price NSE
₹305.40
▼
-9.70 (-3.08%)
Share Price BSE
₹305.45
▼
-9.20 (-2.92%)
Track Cohance Lifesciences share price live with TickJournal's free stock screener.
Analyze Cohance Lifesciences share price history trends and compare 52-week high low
levels.
Calculate COHANCE stock fair value using fundamental analysis and view live share price charts.
Determine Cohance Lifesciences share intrinsic value and compare it with current COHANCE share price.
Record your Cohance Lifesciences trades in TickJournal's free trading journal and track your portfolio performance.
Cohance Lifesciences Market Cap
₹12,073.82 Cr.
COHANCE P/E Ratio (TTM)
42.81
EPS (TTM)
₹10.52
Dividend Yield
-
Debt to Equity
0.09
COHANCE 52 Week High
₹1230.00
Cohance Lifesciences 52 Week Low
₹305.40
Operating Margin
25.00%
Profit Margin
13.72%
COHANCE Revenue (TTM)
₹853.00
EBITDA
₹226.00
Net Income
₹117.00
Total Assets
₹3,032.00
Total Equity
₹1,841.00
Cohance Lifesciences Share Price History - Stock Screener Chart
Screen COHANCE historical share price movements with interactive charts. Analyze price trends and patterns.
Cohance Lifesciences Company Profile - Fundamental Screener
Screen Cohance Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for COHANCE shares.
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Vivek Sharma
ISIN
INE03QK01018
Website
https://www.suvenpharm.com
Cohance Lifesciences Balance Sheet Screener
Screen COHANCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 3,032 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Assets | 889 | 1,263 | 1,011 | 1,128 | 565 | 392 | 390 |
| Fixed Assets | 1,713 | 670 | 663 | 534 | 441 | 357 | 271 |
| Liabilities | |||||||
| Total Liabilities | 3,032 | 2,254 | 1,966 | 1,830 | 1,475 | 1,173 | 783 |
| Current Liabilities | 826 | 97 | 72 | 92 | 74 | 128 | 35 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 1,841 | 2,051 | 1,735 | 1,527 | 1,181 | 845 | 590 |
| Share Capital | 26 | 26 | 26 | 26 | 26 | 13 | 13 |
| Reserves & Surplus | 1,671 | 2,025 | 1,710 | 1,502 | 1,155 | 832 | 578 |
Cohance Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Cohance Lifesciences income statement and profit fundamentals.
Analyze COHANCE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Cohance Lifesciences share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 853 | 564 | 571 | 551 | 270 | 508 | 620 | 323 | 381 | 358 | 251 | 234 | 381 | 350 | 289 |
| Expenses | 627 | 445 | 435 | 454 | 180 | 363 | 398 | 189 | 198 | 181 | 133 | 154 | 207 | 188 | 179 |
| EBITDA | 226 | 118 | 137 | 97 | 90 | 145 | 222 | 133 | 183 | 178 | 118 | 80 | 174 | 162 | 111 |
| Operating Profit % | 25.00% | 19.00% | 22.00% | 17.00% | 29.00% | 26.00% | 34.00% | 38.00% | 47.00% | 48.00% | 42.00% | 30.00% | 43.00% | 45.00% | 36.00% |
| Depreciation | 54 | 45 | 44 | 47 | 17 | 31 | 38 | 20 | 12 | 13 | 12 | 13 | 10 | 12 | 12 |
| Interest | 10 | 10 | 9 | 9 | 2 | 10 | 10 | 3 | 5 | 1 | 1 | 2 | 2 | 2 | 0 |
| Profit Before Tax | 161 | 63 | 84 | 41 | 71 | 103 | 174 | 110 | 166 | 164 | 105 | 66 | 161 | 149 | 99 |
| Tax | 44 | 16 | 17 | 12 | 18 | 28 | 36 | 26 | 42 | 43 | 26 | 19 | 70 | 41 | 26 |
| Net Profit | 117 | 46 | 66 | 29 | 53 | 75 | 138 | 83 | 124 | 121 | 80 | 47 | 92 | 108 | 72 |
| EPS | 3.16 | 1.28 | 1.94 | 0.96 | 2.10 | 1.98 | 3.63 | 3.26 | 4.87 | 4.74 | 3.13 | 1.84 | 3.60 | 4.22 | 2.83 |
Cohance Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen COHANCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 288 | 359 | 457 | 330 | 383 | 407 | 50 |
| Investing Activities | -253 | -362 | -195 | -136 | -311 | -414 | -66 |
| Financing Activities | 3 | -14 | -242 | -156 | -76 | 7 | 26 |
| Net Cash Flow | 38 | -18 | 20 | 37 | -5 | 1 | 11 |
Cohance Lifesciences Shareholding Pattern Screener
See Cohance Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Cohance Lifesciences promoter holding and ownership changes for COHANCE on TickJournal.
| Item | 2025-Mar | 2025-May | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.10% | 66.41% | 66.41% | 57.49% | 57.49% | 50.10% | 50.10% | 50.10% |
| FII Holding | 11.05% | 7.38% | 7.23% | 6.51% | 6.02% | 9.54% | 9.80% | 10.70% |
| DII Holding | 16.60% | 11.02% | 11.40% | 20.82% | 21.57% | 17.24% | 17.42% | 16.94% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 9.68% | 6.63% | 6.40% | 6.42% | 6.76% | 10.51% | 10.08% | 9.75% |
| Other Holding | 12.55% | 8.55% | 8.55% | 8.75% | 8.16% | 12.59% | 12.59% | 12.50% |
| Shareholder Count | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 | 68,932 | 65,777 | 69,337 |
Cohance Lifesciences Share Dividend Screener - Share Yield Analysis
Check Cohance Lifesciences dividend history with payout and yield data.
View Cohance Lifesciences dividend details including ex-dates and amounts for COHANCE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹6.00 | 0.89% |
| 2022-March | ₹5.00 | 1.06% |
| 2021-March | ₹2.00 | 0.32% |
| 2020-March | ₹5.00 | 1.01% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Cohance Lifesciences Stock Index Membership
See which indices include Cohance Lifesciences stock.
Check COHANCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Cohance Lifesciences Market Events Screener - Corporate Actions
Get Cohance Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Cohance Lifesciences stock events that may affect COHANCE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 5.00 /share | -3.05% | ||
| Bonus | 1:1 | 0.04% | ||
| Annual General Meeting | NA | -6.87% | ||
| Dividend | ₹ 1.00 /share | -3.05% | ||
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | -33.96% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -20.48% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -5.19% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -5.13% |
| 2025-05-07 | 2025-05-07 | Change Of Name | NA | 0.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.54% |
| 2024-11-28 | 2024-11-28 | Extraordinary General Meeting | NA | -0.62% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 4.44% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 16.74% |
| 2023-12-15 | 2023-12-15 | Annual General Meeting | NA | 17.68% |
| 2022-05-13 | 2022-05-17 | Dividend | ₹ 1.00 /share | -12.53% |
Cohance Lifesciences Competitors Screener - Peer Comparison
Screen COHANCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Cohance Lifesciences Company Announcements - News Screener
Screen COHANCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-19 | Outcome Of Board Meeting | View |
| 2026-02-19 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2026-02-14 | Cohance Lifesciences Limited Has Informed The Exchange About Additional Information On USFDA Announcement. | View |
| 2026-02-11 | Cohance Lifesciences Limited Has Informed The Exchange About USFDA Announcement. | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2026-01-22 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2026-01-22 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-19 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2026-01-17 | Grant Of Stock Options | View |
| 2026-01-05 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-29 | Closure of Trading Window | View |
| 2025-12-29 | Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine-Months Ending December 31 2025 | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-23 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-12-13 | Intimation Of Change In Website Address Of The Company | View |